TABLE 5.

MB and UB exposure curves and percentage of individuals exceeding the ADI for imazalil and pirimiphos‐methyl.

Substance	Population class	Country	50th Pctl (MB) (%)	50th Pctl (UB) (%)	95th Pctl (MB) (%)	95th Pctl (UB) (%)	99th Pctl (MB) (%)	99th Pctl (UB) (%)	99.9th Pctl (MB) (%)	99.9th Pctl (UB) (%)	Percentage of consumers exceeding ADI (MB) (%)	Percentage of consumers exceeding ADI (UB) (%)
Imazalil	Adults	FI	0.1258	0.1589	1.2902	1.5132	5.2998	7.8074	78.5190	217.2474	0.155	0.348
Imazalil	Adults	DE	0.0136	0.0363	0.7461	0.8556	10.9884	13.3161	46.1980	55.8815	0.010	0.029
Pirimiphos‐methyl	Adults	DE	0.6559	0.8613	2.3594	4.5115	3.8858	7.7976	7.1927	14.7851	0.000	0.019
Pirimiphos‐methyl	Toddlers	BG	2.8313	3.5769	5.8289	6.9596	7.7444	12.1743	42.6831	108.7358	0.000	0.584